A pilot study on the use of interferon beta-1a in early Alzheimer’s disease subjects

Table 1 Adverse events recorded in Placebo-and IFNβ 1-treated subjects

Adverse event	Placebo		IFN β 1a		Total
Severity	Mild	Moderate	Mild	Moderate	Total
Articular pain	2^a	0	0	0	2
Fever	0	0	1^a	0	1
High cholesterol	0	0	3^c	0	3
High level of ALT and AST	0	1^b	0	1^b	2
High pseudocholinesterase	1^c	0	1^c	1^c	3
High triglycerides	0	0	0	1^c	1
High TSH	0	1^c	0	0	1
Low blood pressure	1^c	0	0	0	1
Repolarization ventricular anomaly	0	0	1^c	0	1
Right ear buzzing	1^b	0	0	0	1
Flu-like syndrome	1^c	0	0	0	1
TOTAL	6	2	6	3	17

The number of adverse events in the two treatment arms is reported in details subdivided by severity degree. The relation to drug administration is shown as follows: ^aprobably related; ^bunlikely related; ^cunrelated. ALT, alanine aminotransferase; AST, aspartate aminotransferase; TSH, thyroid stimulating hormone.

ISSN: 1742-2094